Brief: Verve Therapeutics Provides Regulatory Update On Verve-101 And Reports Q3 Financial Results
07/11/2022 11:58
Nov 7 (Reuters) - Verve Therapeutics Inc VERV.O :
* VERVE THERAPEUTICS INC Q3 LOSS PER SHARE $0.79
* VERVE THERAPEUTICS PROVIDES REGULATORY UPDATE ON VERVE-101
INVESTIGATIONAL NEW DRUG APPLICATION AND REPORTS THIRD QUARTER
2022 FINANCIAL RESULTS
* VERVE THERAPEUTICS INC - WELL-CAPITALIZED WITH $550.7
MILLION
SUPPORTING RUNWAY INTO SECOND HALF OF 2025
* VERVE THERAPEUTICS INC - VERVE-101 INVESTIGATIONAL NEW
DRUG
APPLICATION PLACED ON HOLD BY U.S. FOOD AND DRUG ADMINISTRATION
* VERVE THERAPEUTICS INC - DOSING COMPLETED IN FIRST DOSE
COHORT
OF HEART-1 CLINICAL TRIAL OF VERVE-101 IN PATIENTS WITH HEFH
* VERVE-WILL PROVIDE UPDATES PENDING ENGAGEMENT WITH FDA,TO
WORK
CLOSELY WITH FDA TO RESOLVE HOLD AS PROMPTLY AS POSSIBLE TO
INITIATE DOSING IN US
Source text for Eikon: ID:nGNX47sQ9F
Further company coverage: VERV.O
((Reuters.Briefs@thomsonreuters.com;))